DOCSLIB.ORG

MICHAEL J. WELCH, Ph.D. Personal Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MICHAEL J. WELCH, Ph.D. Personal Information CURRICULUM VITAE – MICHAEL J. WELCH, Ph.D. Personal Information: a. Sex: Male b. Birth date: 28 June 1939 c. Birthplace: Stoke-on-Trent, England Citizenship: USA__X__ Other____ Addresses and Telephone Numbers: Office: Division of Radiological Sciences Department of Radiology Washington University School of Medicine 510 South Kingshighway Blvd. Campus Box 8225 St. Louis, Missouri 63110 USA 314-362-8436 314-362-8399 fax Home: 312 N. Meramec #200 St. Louis, MO 63105 314-727-1550 Present Positions: Professor of Radiology Professor of Chemistry Professor of Developmental Biology Professor of Biomedical Engineering Washington University in St. Louis Education: Undergraduate: B.A. Degree in Natural Sciences – Cambridge University, England, 1961 Graduate: M.A. Degree in Natural Sciences – Cambridge University, England, 1964 Ph.D. Degree Chemistry – University of London, England, 1965 1 Academic Position/Employment: 9/62 - 8/65 Graduate Student Queen Mary College Department of Chemistry University of London London, England 9/65 - 9/67 Research Associate Brookhaven National Laboratory Upton, New York 9/67 - 7/70 Assistant Professor of Radiation Chemistry The Edward Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri 9/69 - 1/71 Assistant Professor of Chemistry Department of Chemistry Washington University St. Louis, Missouri 7/70 - 7/74 Associate Professor of Radiation Chemistry The Edward Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri 1/71 - 7/75 Associate Professor of Chemistry Department of Chemistry Washington University St. Louis, Missouri 7/75 - 7/78 Adjunct Professor Department of Chemistry Washington University St. Louis, Missouri 7/74 - 1991 Professor of Radiation Chemistry The Edward Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri 7/78 – present Professor of Chemistry Department of Chemistry Washington University St. Louis, Missouri 7/90 - 12/94 Director, Division of Radiation Sciences The Edward Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri 2 7/91 – present Professor of Radiology The Edward Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri 1/93 – present Professor of Developmental Biology Department of Developmental Biology Washington University School of Medicine St. Louis, Missouri 12/94 – 06/07 Co-Director, Division of Radiological Sciences The Edward Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri 06/00 – present Professor of Biomedical Engineering Department of Biomedical Engineering Washington University in St. Louis St. Louis, Missouri Siteman Cancer Center Activities Member: 1997 – present Head, Oncological Imaging Research Program: 2000 – present Member, Senior Leadership Committee: 2000 – present Co-Director, Small Animal Imaging Core: 2000 – present Honors and Awards: Open Scholarship to St. Catharine’s College Cambridge University, England: 1958 - 1961 Japanese Society for the Promotion of Science Visiting Scholar: 1980. American Chemical Society St. Louis Award, for outstanding contributions to the chemical profession: 1988 National Award for Nuclear Chemistry, for contributions in Fundamental and Applied Nuclear Chemistry: 1990 Midwest Award, for outstanding achievements by a chemist in the Midwest Region: 1991 Society of Nuclear Medicine Paul C. Aebersold Award, for outstanding achievement in Basic Science Applied to Nuclear Medicine: 1980 Berson-Yalow Award, for an outstanding contribution using the principle of Radioimmunoassay: 1988 Berson-Yalow Award, for an outstanding contribution using the principle of Radioimmunoassay: 1990 Georg Charles de Hevesy Nuclear Medicine Pioneer Award, for distinguished contributions to Nuclear Medicine: 1992 Cassen Prize: 2004 The Institute of Medicine Elected Member: 1999 American College of Radiology Honorary Fellow: 2004 International Isotope Society Melvin Calvin Award, for outstanding contributions to the field of isotopes: 2006 3 Society of Molecular Imaging Molecular Imaging Achievement Award, 2007 Society of Nuclear Medicine Michael J. Welch Award (presented annually)-In recognition of his outstanding contributions to the field of Radiopharmaceutical Chemistry, 2008 Academy of Molecular Imaging Distinguished Basic Scientist recipient, 2008 Washington University School of Medicine Second Century Award, 2008 Distinguished Faculty Award for Outstanding Researcher, 2011 Radiological Society of North America Eugene P. Prendegrass New Horizons Lecturer 2008 (Nanotechnology in the future of imaging: Prospects and pitfalls) Washington University School of Medicine Distinguished Faculty Awards; Distinguished Investigator Award, 2011 Professional Societies and Organizations: American Chemical Society Member, Division of Nuclear Chemistry - Technology The Royal Society of Chemistry (London) The Radiation Research Society Sigma Xi International Symposia on Radiopharmaceutical Chemistry Member, International Founding and Organizing Committee: 1978-Present The Society of Nuclear Medicine Program Committee Member: 1969, 1972, 1975, 1983 President-Elect, Missouri Valley Chapter: 1975 - 1977 President, Missouri Valley Chapter: 1977 - 1979 Program Committee Subchairman: 1978, 1979 Member, Board of Directors, Radiopharmaceutical Science Council: 1977 - 1979 Member, Board of Trustees: 1980 - 1990 President, Radiopharmaceutical Science Council: 1980 - 1981 Program Committee Vice-Chairman: 1981, 1984 President-Elect: 1983 - 1984 President: 1984 Chairman, Awards Committee: 1986 - 1988 General Program Chairman: 1988 – 1991 Society of Radiopharmaceutical Chemistry and Biology President: 2001 – 2003 Member, Executive Committee: 2003 – 2006 National Academy of Sciences Member, Subcommittee on Nuclear and Radiochemistry: 1980 - 1982. Member, Committee on Nuclear and Radiochemistry: 1983 - 1986 Co-Chairman, Workshop on Training Requirements for Chemists in Nuclear Medicine, Nuclear Industry and Related Areas: 1988 Diagnostic Radiology Study Section, NIH, Member: July 1986–1991 Chairman: July 1989-1991 The Whitaker Foundation Member, Scientific Advisory Committee: August 1995–2004 Institute of Medicine Member, Clinical Research Roundtable: 2000 - 2004 Member, Board on Health Science Policy: 2003 - 2009 Canada Research Chairs Program 4 Member, Review Committee: September 2000 – present NCI Program Project Review Group Member, Subcommittee E on Cancer Epidemiology, Prevention and Control: 2002-2008 Editorial Activities: Associate Editor, Journal of Computed Tomography: 1978 -1984 Editorial Board, Journal of Nuclear Medicine: 1982 -1988, 2002 - present Associate Editor, Journal of Nuclear Medicine: 1988 – 2002 Past Graduate Students – present positions Berridge, Marc, Ph.D. Professor Department of Radiology University of Arkansas Medical School Frost, John J., M.D., Ph.D. 4301 W. Markham St. Professor Little Rock, AR 72205 Department of Radiology Johns Hopkins Medical Institute Bonasera, Thomas A. Ph.D. 600 N. Wolfe Street Manager, PET and Imaging Center Baltimore, MD 21287-2179 Radiochemistry Glaxo Smith Kline Hennkens, Heather, Ph.D. Greenford Staff Scientist Middlesex, England UB6 OHE Analytical Bio-Chemistry Laboratories, Inc. 7200 E ABC Lane Breaux (Wiegers), Carol, Ph.D. Columbia, MO 65211 Department of Chemistry College of the Ozarks Jiang, W. Victor, Ph.D. Branson, MO Director of Radioimmunoassay Research Kaiser Hospitals Chesis, Paul, M.D., Ph.D. 4131 Geary Blvd. Radiologist San Francisco, CA 94118 Deweese Radiological Group, Inc. 5700 Broadmoor, Suite 900 Jones-Wilson, Michelle, Ph.D. Mission, KS 66202 Associate Professor Department of Chemistry Dischino, Douglas, Ph.D. East Stroudsburg University Senior Research Chemist 200 Prospect St. Bristol-Myers/Squibb East Stroudsburg, PA 18301 P.O. Box 5100, Department 403 Wallingford, CT 06492 Knight, Linda C., Ph.D. Professor Downer, Joanna B., PhD Department of Radiology Senior Associate Temple University Duke University Medical Center 3401 North Broad Street 604 Macon Drive Philadelphia, PA 19140 Wilmington, NC 28412 Loberg, Michael D., Ph.D. Edwards, Barry, Ph.D. Chief Executive Officer Assistant Professor NitroMed, Inc. Washington University School of Medicine 12 Oak Park Drive Division of Radiological Sciences Bedford, MA 01730 510 S. Kingshighway Blvd. St. Louis, MO 63110 McElvany, Karen D., Ph.D. 5 University of North Carolina School of 505 Parnassus Ave. Medicine San Francisco, CA 701 Meadowmont Lane Chapel Hill, NC 27517 Vavere, Amy, Ph.D. Head Radiochemist Molecular Imaging Research Moerlein, Stephen, Ph.D. St. Jude’s Children’s Research Hospital Associate Professor 262 Danny Thomas Place, MS #220 Mallinckrodt Institute of Radiology Memphis, TN 38105 Washington University School of Medicine 510 S. Kingshighway Blvd. Wallace, Susan L., Ph.D. St. Louis, MO 63110 General Manager Philips Radiation Oncology Services Rogers, Buck E., Ph.D. Philips Healthcare Associate Professor 3000 Minuteman Road Department of Radiation Oncology Andover, MA 01810-1099 Washington University School of Medicine 4511 Forest Park Blvd. Zhang, Jian, Ph.D. St. Louis, MO 63108 Sagent Technology, Inc. 800 W. El Camino Real, 3rd Floor VanBrocklin, Henry F., Ph.D. Mountain View, CA 94040 Professor, Department of Radiology Director of Radiopharmaceutical Research University of California San Francisco Select Post-Doctoral Fellows/Collaborators – present positions Anderson, Carolyn
Load more

Recommended publications
  • A Unique Estrogen Receptor-Regulated Gene That Is Activated by Antiestrogens (Electrophile Response Element͞tamoxifen͞antioxidant͞breast Cancer)
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 2581–2586, March 1997 Medical Sciences The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens (electrophile response elementytamoxifenyantioxidantybreast cancer) MONICA M. MONTANO* AND BENITA S. KATZENELLENBOGEN*†‡ *Departments of Molecular and Integrative Physiology and †Cell and Structural Biology, University of Illinois and College of Medicine, Urbana, IL 61801-3704 Communicated by Jack Gorski, University of Wisconsin, Madison, WI, December 30, 1996 (received for review October 4, 1996) ABSTRACT Antiestrogens are thought to exert most of 10 and 11). These widely distributed enzymes detoxify elec- their beneficial effects in breast cancer by antagonizing the trophiles, thereby protecting cells against the toxic and neo- actions of estrogen. We report here that antiestrogens also plastic effects of carcinogens. stimulate the expression of quinone reductase (QR) [NAD- Using the technique of RNA differential display (12), we (P)H:quinone oxidoreductase, EC 1.6.99.2], which may pro- have identified in this report QR mRNA as a species that is vide protective effects against the toxicity and mutagenicity expressed at much higher levels in an MCF-7 breast cancer cell caused by quinones. QR is up-regulated by low concentrations subline that has been grown long term in the presence of the of antiestrogens (trans-hydroxytamoxifen, tamoxifen, and antiestrogen trans-hydroxytamoxifen (TOT) (13). We there- ICI182,780) in estrogen receptor (ER)-containing breast can- fore undertook the examination of its regulation by antiestro- cer cells, and this increase is suppressed by estrogen via an gens as a possible basis for the proposed antioxidant action of ER-dependent mechanism.
    [Show full text]
  • February 18, 1999
    6/20/2020 Curriculum Vitae John A. Katzenellenbogen Contact Information: 461 Roger Adams Laboratory, Box 37 Dept. of Chemistry, Univ. of Illinois 600 South Mathews Avenue 217 333 6310 (office) Fax: 217 333 7325 Urbana, Illinois 61801 E-mail: [email protected] Biographical Background: Place of Birth: Poughkeepsie, New York Citizenship: USA Educational Background: B.A. Chemistry (Summa cum laude) Harvard College 1962-66 M.A. Chemistry Harvard University 1966-67 Ph.D. Chemistry Harvard University 1967-69 (Research Advisor: E. J. Corey) Professional Employment: University of Illinois at Champaign-Urbana Assistant Professor of Chemistry 1969–1975 Associate Professor of Chemistry 1975–1979 Professor of Chemistry 1979–present Beckman Institute Affiliate 1988–present Roger Adams Professor of Chemistry 1992–1996 Swanlund Professor of Chemistry 1996-present Professor of Bioengineering (joint appointment) 2001-present Awards, Fellowships, Honors: Award for Outstanding Achievement in Chemistry in Cancer Research, American Association for Cancer Research (2018) Medicinal Chemistry Hall of Fame, American Chemical Society (2018) The President’s Award, Society for Radiopharmaceutical Sciences (2017) Fred Conrad Koch Lifetime Achievement Award, The Endocrine Society [with Benita Katzenellenbogen] (2016) Inaugural Philip Portoghese Lectureship in Medicinal Chemistry, American Chemical Society (2010) Royal Society of Chemistry Centenary Lectureship Award (2009) Leading Edge in Basic Science Award, Society of Toxicology (2010) Gustavus John Esselen Award
    [Show full text]
  • New Compounds Block Master Regulator of Cancer Growth, Metastasis 7 January 2020, by Diana Yates
    New compounds block master regulator of cancer growth, metastasis 7 January 2020, by Diana Yates The researchers focused on FOXM1 because it is found in higher abundance in cancer cells than in healthy human cells, said Benita Katzenellenbogen, a University of Illinois professor of molecular and integrative physiology who led the study with U. of I. chemistry professor John Katzenellenbogen and life sciences research specialist Yvonne Ziegler. "FOXM1 is a key factor that makes breast cancer and many other cancers more aggressive and more difficult to treat," Benita Katzenellenbogen said. "Because it is a master regulator of cancer growth and metastasis, there has been great interest in developing compounds that would be effective in blocking it." Researchers including, from left, graduate student Valeria Sanabria Guillen, research scientist Sung Hoon So far, no successful drug agents have been Kim, researcher Kathy Carlson, chemistry professor developed to reduce the effects of FOXM1, John John Katzenellenbogen, research specialist Yvonne Katzenellenbogen said. Ziegler, and molecular and integrative physiology professor Benita Katzenellenbogen developed new drug "There are reports of other inhibitors of FOXM1, but agents to inhibit a pathway that contributes to cancer. these are generally less potent and do not work The compounds killed cancer cells and reduced the growth of breast cancer tumors in mice. Credit: L. Brian well in the body," he said. "Our compounds have Stauffer good anti-tumor activity in animal models. They behave well in vivo and have long half-lives in the blood. Some work well when given orally, which is desirable for ultimate patient use." Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM1, a The researchers developed the new drugs by transcription factor that regulates the activity of analyzing the properties of various compounds in a dozens of genes.
    [Show full text]
  • From the Editors
    CICR NEWSLETTER – June 2018 From the Editors This quarter, following the AACR Annual Meeting 2018, we have chosen to focus on “Contributions of Rational Drug Design towards Precision Medicine.” CICR Editor, Dr. Zoe Cournia, and CICR Editor-elect, Dr. Alex Waterson, along with CICR Editorial Board members, Drs. Iain Watson; Terry Moore; and Martin Swarbrick, have assembled an overview of the topic. In this newsletter, you will also find Selected Research Highlights on precision medicine and recent FDA approvals and the related Profile of the Early-career Researcher, Dr. Steve Staben, of Genentech, along with Global News, Upcoming Conferences, Funding Opportunities, and, of course, an update from Prof. Julian Blagg, CICR Working Group Chairperson, on CICR news and activities. Contributions of rational drug design towards precision medicine Rational drug design began to rise to prominence in the 1980s, superseding a model for drug discovery based more on synthetic organic chemistry and high throughput screening, fueled by significant and continual increases in computing power and advances in structural biology. The antiviral zanamivir is widely acknowledged as one of the first marketed drugs to have been identified by rational design: in what now seems a very familiar approach, X-ray crystallographic data facilitated an understanding of the structure of neuraminidase leading to the discovery and development of this transition-state analogue inhibitor. Additional drugs designed rationally in the 1990s include Saquinavir, discovered based on peptide derivatives that were transition- state mimetics of a sequence found in several retroviral substrates, and ritonavir, utilizing rational design on the structure of the C2-symmetric homodimer structure of HIV-1 PR, which has a single active site.
    [Show full text]
  • Commencement 1991-2000
    Jlfek BUMS} *_y#e Johns Hopkins University # ConfejTing of Degrees at the Close of the 1 1 1th Academic Year * A% 24, 72P5 Digitized by the Internet Archive in 2012 with funding from LYRASIS Members and Sloan Foundation http://archive.org/details/commencement1993 JOHNSUNIVERSITYHOPKINS Office of the Registrar 75 Garland Hall / 3400 N. Charles Street July ,1993 Baltimore MD 21218-2688 (410)516-8080 For those who use the Commencement Program as an official record of the awarding of degrees, please note the following changes to the 1993 Commencement Program: 1. Bachelor of Arts (Arts and Sciences) pages 22-24 Add: Chi Yung Ann Charles Neilson Curlett, Jr. Laura E. Greenwald Zubin Razzaque Khan Delete: Cholmin I. Ann Robert Wayne Jenkins Douglas Allen Besen Dennis Joseph McDonald Paul Anthony Brown Emily M. Miller Renan Carlos Castillo Michelle Nance Leon Chao Kate Byxbe Pessin James Edward Crawford Carlos Antonio Pfeiffer Robert James Dunn David Evan Ross Kelly Lynn Grey Adwoa Aya Sanderson Lover Highjr. Robert Marshall Searles Jane Jungeon Hong Catherine Hughes Tokheim Jeffrey Michael Wills 2. Bachelor of Science in Biomedical Engineering (Engineering) page 24 Add: Irian Amanat 3. Bachelor of Science in Chemical Engineering (Engineering) page 24 Delete: Robert William Apollo 4. Bachelor of Science in Electrical Engineering (Engineering) page 25 Delete: John Joseph Pollock 5. Bachelor of Science in Mathematical Science (Engineering) page 25 Delete: Matthew DeBari Junge 6. Performer's Certificates (Peabody) page 26 Add: Eddie Forest Stallings, Jr. Voice . 7. Bachelor of Music (Peabody) page 26 Add: Eddie Forest Stallings, Jr. Music Education Max Vont. Violin 8.
    [Show full text]
  • Molecular Determinants of Tissue Selectivity in Estrogen Receptor Modulators
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14105–14110, December 1997 Pharmacology Molecular determinants of tissue selectivity in estrogen receptor modulators TIMOTHY A. GRESE*, JAMES P. SLUKA*, HENRY U. BRYANT,GEORGE J. CULLINAN,ANDREW L. GLASEBROOK, CHARLES D. JONES,KEN MATSUMOTO,ALAN D. PALKOWITZ,MASAHIKO SATO,JOHN D. TERMINE, MARK A. WINTER,NA N. YANG, AND JEFFREY A. DODGE* Endocrine Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 Edited by Paul Talalay, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved October 3, 1997 (received for review July 3, 1997) ABSTRACT Interaction of the estrogen receptoryligand molecular conformation of individual ligands (11–14). The complex with a DNA estrogen response element is known to recent characterization of a new ER isoform, ERb, adds a regulate gene transcription. In turn, specific conformations of further layer of complexity, because ligands with different the receptor-ligand complex have been postulated to influence structural characteristics may exhibit different binding profiles unique subsets of estrogen-responsive genes resulting in differ- depending on which ER isoform is being evaluated (15, 16). ential modulation and, ultimately, tissue-selective outcomes. The To date, ER ligands have been grouped into four classes on the estrogen receptor ligands raloxifene and tamoxifen have dem- basis of in vivo pharmacology, and representatives of these classes onstrated such tissue-specific estrogen agonistyantagonist ef- indeed have been shown to exhibit unique profiles with respect to fects. Both agents antagonize the effects of estrogen on mammary transcriptional activation (9). Differential effects on mammary, tissue while mimicking the actions of estrogen on bone.
    [Show full text]
  • The Androgen Derivative 5A-Androstane-3B,17B-Diol Inhibits Prostate Cancer Cell Migration Through Activation of the Estrogen Receptor B Subtype
    Research Article The Androgen Derivative 5A-Androstane-3B,17B-Diol Inhibits Prostate Cancer Cell Migration Through Activation of the Estrogen Receptor B Subtype Vittoria Guerini,1 Daniela Sau,1 Eugenia Scaccianoce,1 Paola Rusmini,1 Paolo Ciana,3 Adriana Maggi,3 Paolo G.V. Martini,4 Benita S. Katzenellenbogen,4 Luciano Martini,1 Marcella Motta,1,2 and Angelo Poletti1 1Institute of Endocrinology, 2Center for Endocrinological Oncology, and 3Department of Pharmacological Sciences, University of Milan, Italy; and 4Department of Molecular and Integrative Physiology, University of Illinois, Urbana-Champaign, Illinois Abstract androgen blockade. Most patients initially respond to androgen Prostate cancer growth depends, in its earlier stages, on ablation therapies, but relapse with hormone-refractory prostate androgens and is usually pharmacologically modulated with cancer (3), as a consequence of clonal selection of androgen- androgen blockade. However, androgen-ablation therapy may independent foci. Androgen-resistant tumors are generally charac- generate androgen-independent prostate cancer, often char- terized by an increased invasiveness. Therefore, it is important to find new approaches to control prostate cancer progression acterized by an increased invasiveness. We have found that the 5A-reduced testosterone derivative, dihydrotestosterone (the towards androgen-insensitivity. most potent natural androgen) inhibits cell migration with an In prostate cells, testosterone, is first irreversibly reduced by the a androgen receptor–independent
    [Show full text]
  • MCB Permit No
    A Magazine | The School of Molecular and Cellular Biology at the University of Illinois at Urbana-Champaign | Issue 9, 2015 University of Illinois at Urbana-Champaign School of Molecular and Cellular Biology Nonprofit org. U.S. postage 393 Morrill Hall PAID 505 South Goodwin Avenue Champaign, IL MCB Permit no. 75 Urbana, IL 61801 mcb.illinois.edu UMBRELLA OPPORTUNITIES: GRADUATE PROGRAM GIVES STUDENTS CHANCE TO EXPLORE College of Liberal Arts and Sciences LETTER FROM THE DIRECTOR TABLE OF CONTENTS 4 Umbrella Opportunities Graduate Program Gives Students Chance to Explore It was a beautiful fall in Champaign Illinois, reminiscent of what was typical before 6 Heart and Splicy Development the last couple of years of early snow. Matching the sunny weather is the warm glow The Kalsotra Lab reflected by the accomplishments of our faculty, staff, students and alumni that we 7 Targeting Cancer with T Cells are pleased to share with you in this edition of our annual magazine. David Kranz, PhD ’82, Microbiology 8 First in Class In October we celebrated the success of three alumni who were recognized by the Guy Padbury, MS ’85, PhD ’88, Biochemistry College of Liberal Arts and Sciences during their homecoming celebration. Tom 9 Gene taranis Key to Regeneration of Fruit Fly Epithelial Tissues Cycyota (B.S. ’80 Biology) received the LAS Humanitarian Award for his Smith-Bolton Lab outstanding service as President and CEO of AlloSource. His work to improve the lives of many through the use of donated human tissue is legendary. At the same 10 An Interview with Ann Carpenter PhD ’03, Cell and Developmental Biology event, an LAS Alumni Achievement Award was bestowed upon David Kranz (M.S.
    [Show full text]
  • Mastfff Chicago, Illinois PREFACE
    CONF-92QU37- DB93 010828 PROCEEDINGS OF A WORKSHOP ON MOLECULAR NUCLEAR MEDICINE Embassy Row Hotel, 2015 Massachusetts Avenue, N.W. Was! ington, D.C. January 23-24, 1992 Prepared by: U.S. Department of Energy Medical Applications and Biophysical Research Division Office of Health and Environmental Research Washington, D.C. 20585 Editor, Richard C. Reba The University of Chicago MASTfff Chicago, Illinois PREFACE Molecular Nuclear Medicine is developing into a new research area to improve the health and welfare of the public. Within the Department of Energy, the Program in Molecular Nuclear Medicine will support novel molecular approaches for diagnostic and therapeutic applications of nuclear medicine. To exploit the opportunities presented by the revolution in the biological sciences, the strategy is to integrate the scientific and technical power of molecular biology with the existing nuclear medicine program at the Department of Energy. Research in molecular biology has provided significant Insight Into the mechanisms of macromolecular Interactions underlying normal genetic, cellular and physiological processes. Any Insult (arising from diet, drug abuse, environmental exposure, Infection, etc.) that undermines these natural mechanisms can disrupt macromoiecular interactions and regulatory functions, leading to pathological states and disease. Molecular technologies, when coupled with the range of Instrumentation and techniques of nuclear medicine, have the potential to provide tools of much higher sensitivity and precision for detecting, localizing and, potentially for ameliorating, macromolecular, cellular and systemic pathologies. The Workshop represents the Department of Energy's commitment to accelerate the integration of molecular biology and biotechnology with nuclear medicine, and to develop an Innovative Molecular Nuclear Medicine Research Program.
    [Show full text]
  • DECEMBER 2015 NEWSLETTER GREETINGS from the HEAD Milan Bagchi in THIS ISSUE Welcome to the 2015 Edition of the MIP Newsletter
    DECEMBER 2015 NEWSLETTER GREETINGS FROM THE HEAD Milan Bagchi IN THIS ISSUE Welcome to the 2015 edition of the MIP newsletter. As you turn its pages, you will come across an article Greetings from the Head by Milan Bagchi 1 that describes the early history of our department. You will be impressed that physiology has a long and Progress In Women’s rich tradition at the University of Illinois. The University Reproductive Health and opened its doors in 1867 and physiology was taught as a Fertility subject starting in 1871. A long line of dedicated faculty members continued by Jeanne Bullock Goldberg 2-3 to carry the flag of physiology until the department was formally established Physiology at University of in 1949 with R.E. Johnson as Head. In 1959, the department moved to its Illinois, Urbana-Champaign: The current location in Burrill Hall. For the past 66 years, the department has First Hundred Years (1870-1970) continued to thrive as one of the oldest and most prestigious physiology by Deb Aronson 4-5 departments in the nation recognized for its cutting edge research in comparative physiology, cardiovascular physiology, biophysics, neuroscience, MIP family news 5-6 endocrinology, reproductive biology, and metabolic health. Recent Publications 7 A watershed event this year was the announcement that the University of Illinois Regional College of Medicine (COM) at Urbana-Champaign will close ABOUT THE its doors within the next few years. The Carle Illinois College of Medicine, an NEWSLETTER engineering-based medical school, will take its place. One cannot help but feel a bit nostalgic about the old COM, which was intimately associated with The Molecular and Integrative Physiology Newsletter is an annual publication of the our department and provided such stellar faculty as Benita Katzenellenbogen, Department of Molecular and Integrative Byron Kemper, Martha Gillette, David Sherwood, Phil Best, and many others.
    [Show full text]